Cavers Greg, the Chief Financial Officer of Helus Pharma Inc., has made a notable acquisition of shares, as detailed in a recent SEC filing. This transaction, involving 3,000 shares at a price of $12.91 each, demonstrates Greg's confidence in the company's prospects.
Helus Pharma Inc., identified by the SEC with the CIK 0001833141, operates within the pharmaceutical preparations sector. The company has been active in the market, as reflected in its recent filings, including a Form 3 and this Form 4 submitted on October 1, 2026.
According to the filing, dated September 29, 2026, Cavers acquired the shares, which he holds indirectly through his spouse. Following this transaction, he now owns a total of 125,937 shares of Helus Pharma. The filing states, "Cavers Greg acquired 3,000 shares at a price of $12.91 each, demonstrating a significant investment in the company." The transaction was reported under the SEC Act of 1934.
This acquisition may impact various stakeholders, including current and potential investors, as it reflects the CFO's belief in the company's future performance. The pharmaceutical industry is known for its competitive nature, and such insider transactions can influence market perceptions.
The filing does not say what happens next, leaving investors and analysts to speculate on the implications of this acquisition.